Clinical trial
Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV
NCT00266526 · Allergopharma GmbH & Co. KG, Industry · Completed
Key facts
| NCT number | NCT00266526 |
|---|---|
| Title | Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV |
| Official title | A Bicentre Open Label Randomised Pilot Study for Proof of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1-FV Versus a Depot Extract of Natural Birch Allergen |
| Lead sponsor | Allergopharma GmbH & Co. KG, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Birch Pollen Allergy |
| Intervention type | Biological |
| Interventions | Recombinant birch pollen |
| Start date | Jul 1, 2003 |
| Primary completion | Jul 1, 2004 |
| Completion | Jul 1, 2005 |
| First posted | Dec 19, 2005 |
| Last update posted | Mar 4, 2013 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: